January 2024: The ‘detective’ researcher hoping to fight cancer with a single dose
Currus Biologics, inventor and scientific advisor Clare Slaney shares her typical day - from treadmill to lab bench to office with a focus on translating her novel CAR T-cell research.
October 2023: Currus Biologics builds out clinical advisory team
Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology has further expanded its clinical advisory team as it advances towards a first in human clinical trial.
October 2022: BIO-Europe 2022 Attendance
Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology will attend this year’s BIO-Europe Convention.
February 2022: Currus Biologics Best Newcomer award Governor of Victoria Start-up Awards Melbourne, Australia
Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology, is excited to announce that it has been named Best Newcomer of the Year in the inaugural Governor of Victoria Start-up Awards.
September 2022: Presentation at CAR-TCR Summit
Currus Biologics, a biotechnology company focused on improving lives by developing CAR T-cell therapy for solid tumour indications using its BEAT technology, announced today that its Chief Executive Officer, Sam Cobb, has been invited to present at the 7th CAR -TCR Summit in Boston 19-22 September 2022.
June 2021: $10m invested into start-up developing new treatments targeting the use of CAR-T cell therapies against solid tumours
Currus Biologics raises $10 million Series A investment from leading life science Venture Capital investors Brandon Capital-managed Medical Research Commercialisation Fund (MRCF) and Uniseed. The funding will be used to advance the Currus Biologics technology to the clinic and improve the success of CAR-T cell therapies against solid tumours such as breast, ovarian and pancreatic cancers.
May 2021: Currus Biologics researchers publish in high impact journal, Journal for ImmunoTherapy of Cancer
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. Journal for ImmunoTherapy of Cancer 2021;9:e002555. doi: 10.1136/jitc-2021-002555
May 2021: Currus Biologics pivotal publication in PNAS
Enterotoxins can support CAR T cells against solid tumors. Proceedings of the National Academy of Sciences Dec 2019, 116 (50) 25229-25235; DOI: 10.1073/pnas.1904618116
May 2021: Bench and Beyond: Tales from Peter Mac Postdoc and Head of R&D at Currus Biologics Clare Slaney
Stories, perspectives, experiences and views from Peter Mac's emerging research leaders.